纤维化分期与非酒精性脂肪性肝病患者结局的关联:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项队列研究共4428例NAFLD患者(其中2875例报告为NASH),以活检纤维化0期为参照,计算各纤维化分期对死亡和肝脏相关事件的相对风险。结果显示纤维化分期越高,全因死亡、肝病死亡、肝移植及肝脏相关事件风险均显著增加。
要点
- 活检证实的纤维化分期是NAFLD患者预后分层的重要依据。
- 纤维化4期较0期的全因死亡风险RR为3.42(95%CI 2.63-4.46)。
- 肝病死亡和肝脏相关事件风险在纤维化4期显著升高。
核心结论
- 活检证实的纤维化与NAFLD患者死亡风险和肝脏相关疾病风险相关,在调整混杂因素后及报告为NASH的患者中亦然。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane Library和试验注册库至2018年8月,纳入成人NAFLD或NASH的前瞻性或回顾性队列研究。
- 共纳入13项研究、4428例NAFLD患者,其中2875例报告为NASH。
主要发现
- 以纤维化0期为参照,纤维化4期的全因死亡RR为3.42(95%CI 2.63-4.46)。
- 纤维化4期的肝病死亡RR为11.13(95%CI 4.15-29.84)。
- 纤维化4期的肝移植RR为5.42(95%CI 1.05-27.89)。
- 纤维化4期的肝脏相关事件RR为12.78(95%CI 6.85-23.85)。
- 在NASH亚组中调整年龄或性别等混杂因素后,RR幅度无显著差异;3项研究探讨纤维化增加对生活质量的影响,结果不一致。
临床怎么用
- 可将活检纤维化分期用于NAFLD患者的预后风险评估和分层管理。
局限性
- 需要进一步研究评估纤维化分期与患者生活质量的关联。
- 尚需确立肝纤维化分期变化作为临床试验有效终点的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Biopsy-confirmed liver fibrosis is a prognostic factor for patients with nonalcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the prognostic value of fibrosis stage in patients with NAFLD and the subgroup of patients with nonalcoholic steatohepatitis (NASH) and to assess the evidence that change in fibrosis stage is a surrogate endpoint. METHODS: We searched the MEDLINE, Embase, Cochrane Library, and trial registry databases through August 2018 for prospective or retrospective cohort studies of liver-related clinical events and outcomes in adults with NAFLD or NASH. We collected data on mortality (all cause and liver related) and morbidity (cirrhosis, liver cancer, and all liver-related events) by stage of fibrosis, determined by biopsy, for patients with NAFLD or NASH. Using fibrosis stage 0 as a reference population, we calculated fibrosis stage-specific relative risk (RR) and 95% confidence interval (CI) values for mortality and morbidities. We performed fixed-effect and random-effect model meta-analyses. Metaregression was used to examine associations among study design (prospective vs retrospective cohort), overall risk of bias (medium or high), and mean duration of follow-up (in years). RESULTS: Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH. Compared with no fibrosis (stage 0), unadjusted risk increased with increasing stage of fibrosis (stage 0 vs 4): all-cause mortality RR, 3.42 (95% CI, 2.63-4.46); liver-related mortality RR, 11.13 (95% CI, 4.15-29.84); liver transplant RR, 5.42 (95% CI, 1.05-27.89); and liver-related events RR, 12.78 (95% CI, 6.85-23.85). The magnitude of RR did not differ significantly after adjustment for confounders, including age or sex in the subgroup of NAFLD patients with NASH. Three studies examined the effects of increasing fibrosis on quality of life had inconsistent findings. CONCLUSIONS: In a systematic review and meta-analysis, we found biopsy-confirmed fibrosis to be associated with risk of mortality and liver-related morbidity in patients with NAFLD, with and without adjustment for confounding factors and in patients with reported NASH. Further studies are needed to assess the association between fibrosis stage and patient quality of life and establish that change in liver fibrosis stage is a valid endpoint for use in clinical trials.
引用
- Taylor RS, Taylor RJ, Bayliss S, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020. PMID: 32027911. doi:10.1053/j.gastro.2020.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。